Investigating how a specific enzyme affects fungal infections in immunocompromised patients

Sphingosine kinase and cryptococcal granuloma

NIH-funded research State University New York Stony Brook · NIH-11126917

This study is looking at how a specific protein called sphingosine kinase 1 helps the body fight off a fungal infection that can be especially dangerous for people with weakened immune systems, like those undergoing certain treatments, to find better ways to treat this infection and its serious complications.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionState University New York Stony Brook NIH-funded
Lab location1 site (Stony Brook, United States)
Project IDNIH-11126917 on NIH RePORTER

What this research studies

This research focuses on understanding the role of sphingosine kinase 1 (SK1) in controlling infections caused by the fungus Cryptococcus neoformans, particularly in individuals with weakened immune systems. Using a mouse model that simulates human granuloma, the study examines how the SK1 pathway influences the body's response to this fungal infection. The research aims to uncover mechanisms that lead to severe complications, such as meningo-encephalitis, when the infection spreads to the brain. Insights gained could inform treatment strategies for patients at risk of cryptococcosis, especially those undergoing therapies that affect immune function.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals with immunodeficiency, such as those living with HIV/AIDS or patients undergoing immunosuppressive therapies.

Not a fit: Patients with strong immune systems or those not at risk for cryptococcal infections may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment strategies for patients with weakened immune systems, reducing the risk of severe fungal infections.

How similar studies have performed: Previous studies have shown that targeting the SK1 pathway can influence fungal infections, indicating potential for success in this area of research.

Where this research is happening

Stony Brook, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency SyndromeAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency SyndromeAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.